CVS Crushes Q2 Estimates, Raises Full-Year Profit Outlook
CVS sits 75% above its 52-week low of $61.35.
Summary
CVS Health delivered a massive Q2 beat, with adjusted EPS of $2.58 nearly 40% above the $1.85 consensus, driven by a sharp rebound in its Health Care Benefits segment. Revenue surged to $106.1 billion, well ahead of the $100.1 billion estimate, while the medical benefit ratio improved to 87.4% versus the expected 90.03%. Management raised full-year adjusted EPS guidance to $7.90-$8.10, significantly above the $7.45 Street view, and set cash flow from operations at $11.5 billion or more. The company also detailed new GLP-1 initiatives, including $29 MinuteClinic virtual visits and transparent pricing for Zepbound and Foundayo by early Q4, building on its recent weight-management program revamp. This follows a series of positive developments, including projected Medicare Advantage rate increases and expanded GLP-1 coverage, though legal overhangs from the Florida AG subpoena and FTC settlement remain. The stock, trading near its 52-week high, is likely to see strong upward pressure on these results.
At the time of this announcement, CVS was trading at $107.50 on NYSE in the Trade & Services sector, with a market capitalization of approximately $133.2B. The 52-week trading range was $61.35 to $110.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.